Clinical Trial Update: Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing gemcitabine and camrelizumab plus apatinib vs cisplatin as first-line therapy for nasopharyngeal carcinoma is ongoing/recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• CISPLATIN (cisplatin)
• Camrelizumab (camrelizumab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: RECRUITING